Breakthroughs in the world of psychedelics are gaining momentum, and investors are taking notice. Research into the therapeutic potential of substances derived from mushrooms and LSD has long been shrouded in controversy, but a growing body of evidence suggests these compounds may hold the key to treating a range of mental health disorders. With promising results from clinical trials and a growing number of companies exploring the commercial potential of these treatments, it's becoming increasingly clear that the concept of using psychedelics to heal the mind is no longer the stuff of science fiction. As the stigma surrounding these substances begins to lift, we're seeing a surge in investment and interest in the development of novel therapies that harness the power of psychedelics to improve lives.
Commercial success is looking less theoretical for treatments based on mushrooms and LSD
